Phathom Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for gastrointestinal diseases. They have the rights to vonoprazan, a P-CAB that blocks acid secretion in the stomach, and are currently in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and Helicobacter pylori infection. The company was founded in 2018 and is based in New Jersey.